Overview

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Status:
Completed

Trial end date:
2017-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Japanese patients with recurrent mature B-cell neoplasms.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Collaborator:

Pharmacyclics LLC.